per dose 300 mg), then increased in steps of up to
5 mg/kg twice daily, adjusted according to response,
dose to be adjusted at weekly intervals; maintenance
15 mg/kg twice daily; maximum 46 mg/kg per day
▶ Adult: Initially 300 mg twice daily, then increased in
steps of up to 600 mg daily, adjusted according to
response, dose to be adjusted at weekly intervals; usual
dose 0.6–2.4 g daily in divided doses
Treatment of primary generalised tonic-clonic seizures
▶ Adult: Initially 300 mg twice daily, then increased in
steps of up to 600 mg daily, adjusted according to
response, dose to be increased at weekly intervals;
usual dose 0.6–2.4 g daily in divided doses
DOSE ADJUSTMENTS DUE TO INTERACTIONS
▶ In adjunctive therapy, the dose of concomitant
antiepileptics may need to be reduced when using high
▶ In adults Not licensed for the treatment of primary
generalised tonic-clonic seizures.
l CAUTIONS Avoid in Acute porphyrias p. 1058 . cardiac
conduction disorders . heart failure . hyponatraemia
l INTERACTIONS → Appendix 1: antiepileptics
antidiuretic hormone secretion like-syndrome . neutropenia . speech impairment
l ALLERGY AND CROSS-SENSITIVITY Caution in patients with
hypersensitivity to carbamazepine. Antiepileptic
hypersensitivity syndrome associated with oxcarbazepine.
See under Epilepsy p. 305 for more information.
l PREGNANCY See also Pregnancy in Epilepsy p. 305.
Monitoring The dose should be monitored carefully during
pregnancy and after birth, and adjustments made on a
l BREAST FEEDING Amount probably too small to be
harmful but manufacturer advises avoid.
l HEPATIC IMPAIRMENT Manufacturer advises caution in
severe impairment (no information available).
Dose adjustments ▶ In adults Halve initial dose if eGFR less
response at intervals of at least 1 week.
▶ In children Halve initial dose if estimated glomerular
filtration rate less than 30 mL/minute/1.73 m2
according to response at intervals of at least 1 week.
l PRE-TREATMENT SCREENING Test for HLA-B*1502 allele in
individuals of Han Chinese or Thai origin (avoid unless no
alternative—risk of Stevens-Johnson syndrome in
presence of HLA-B*1502 allele).
BNF 78 Epilepsy and other seizure disorders 321
▶ Monitor plasma-sodium concentration in patients at risk
▶ Monitor body-weight in patients with heart failure.
l PRESCRIBING AND DISPENSING INFORMATION Patients
may need to be maintained on a specific manufacturer’s
branded or generic oxcarbazepine product.
Switching between formulations Care should be taken when
switching between oral formulations. The need for
continued supply of a particular manufacturer’s product
should be based on clinical judgement and consultation
with the patient or their carer, taking into account factors
such as seizure frequency and treatment history.
Blood, hepatic, or skin disorders Patients or their carers
should be told how to recognise signs of blood, liver, or
skin disorders, and advised to seek immediate medical
attention if symptoms such as lethargy, confusion,
muscular twitching, fever, rash, blistering, mouth ulcers,
bruising, or bleeding develop.
Medicines for Children: Oxcarbazepine for preventing seizures
www.medicinesforchildren.org.uk/oxcarbazepine-preventingseizures
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug. Forms available
from special-order manufacturers include: oral suspension
CAUTIONARY AND ADVISORY LABELS 3, 8
EXCIPIENTS: May contain Propylene glycol
▶ Trileptal (Novartis Pharmaceuticals UK Ltd)
Oxcarbazepine 60 mg per 1 ml Trileptal 60mg/ml oral suspension
sugar-free | 250 ml P £48.96 DT = £48.96
CAUTIONARY AND ADVISORY LABELS 3, 8
▶ Oxcarbazepine (Non-proprietary)
Oxcarbazepine 150 mg Oxcarbazepine 150mg tablets | 50 tablet P £11.14 DT = £8.37
Oxcarbazepine 300 mg Oxcarbazepine 300mg tablets |
Oxcarbazepine 600 mg Oxcarbazepine 600mg tablets | 50 tablet P £45.19 DT = £38.71
▶ Trileptal (Novartis Pharmaceuticals UK Ltd)
Oxcarbazepine 150 mg Trileptal 150mg tablets | 50 tablet P £12.24 DT = £8.37
Oxcarbazepine 300 mg Trileptal 300mg tablets | 50 tablet P £24.48 DT = £5.86
Oxcarbazepine 600 mg Trileptal 600mg tablets | 50 tablet P £48.96 DT = £38.71
Adjunctive treatment of focal seizures with or without
secondary generalised seizures
▶ Child 12–17 years: Initially 2 mg once daily, dose to be
taken before bedtime, then increased, if tolerated, in
steps of 2 mg at intervals of at least every 2 weeks,
adjusted according to response; maintenance 4–8 mg
once daily; maximum 12 mg per day
▶ Adult: Initially 2 mg once daily, dose to be taken before
bedtime, then increased, if tolerated, in steps of 2 mg
at intervals of at least every 2 weeks, adjusted
according to response; maintenance 4–8 mg once
Adjunctive treatment of primary generalised tonic-clonic
▶ Child 12–17 years: Initially 2 mg once daily, dose to be
taken before bedtime, then increased, if tolerated, in
steps of 2 mg at intervals of at least every 2 weeks,
adjusted according to response, maintenance up to
8 mg once daily; maximum 12 mg per day
▶ Adult: Initially 2 mg once daily, dose to be taken before
bedtime, then increased, if tolerated, in steps of 2 mg
at intervals of at least every 2 weeks, adjusted
according to response, maintenance up to 8 mg once
DOSE ADJUSTMENTS DUE TO INTERACTIONS
▶ Titrate at intervals of at least 1 week with concomitant
carbamazepine, fosphenytoin, oxcarbazepine, or
l INTERACTIONS → Appendix 1: antiepileptics
l PREGNANCY Manufacturer advises avoid. See also
Monitoring The dose should be monitored carefully during
pregnancy and after birth, and adjustments made on a
l BREAST FEEDING Avoid—present in milk in animal studies.
l HEPATIC IMPAIRMENT Manufacturer advises caution in
mild to moderate impairment; avoid in severe impairment.
Dose adjustments Manufacturer advises maximum 8 mg
per day in mild to moderate impairment.
l RENAL IMPAIRMENT Avoid in moderate or severe
l PRESCRIBING AND DISPENSING INFORMATION
Switching between formulations Care should be taken when
switching between oral formulations. The need for
continued supply of a particular manufacturer’s product
should be based on clinical judgement and consultation
with the patient or their carer, taking into account factors
such as seizure frequency and treatment history.
Patients may need to be maintained on a specific
manufacturer’s branded or generic perampanel product.
Driving and skilled tasks Manufacturer advises patients and
carers should be cautioned on the effects on driving and
performance of skilled tasks—increased risk of dizziness
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug. Forms available
from special-order manufacturers include: oral suspension
CAUTIONARY AND ADVISORY LABELS 3, 8
EXCIPIENTS: May contain Sorbitol
Perampanel 500 microgram per 1 ml Fycompa 0.5mg/ml oral
suspension sugar-free | 340 ml P £127.50
CAUTIONARY AND ADVISORY LABELS 3, 8, 25
Perampanel 2 mg Fycompa 2mg tablets | 7 tablet P £35.00 DT =
£35.00 | 28 tablet P £140.00 DT = £140.00
Perampanel 4 mg Fycompa 4mg tablets | 28 tablet P £140.00
Perampanel 6 mg Fycompa 6mg tablets | 28 tablet P £140.00
Perampanel 8 mg Fycompa 8mg tablets | 28 tablet P £140.00
Perampanel 10 mg Fycompa 10mg tablets | 28 tablet P £140.00 DT = £140.00
Perampanel 12 mg Fycompa 12mg tablets | 28 tablet P £140.00
322 Epilepsy and other seizure disorders BNF 78
Tonic-clonic seizures | Focal seizures
▶ Child 1 month–11 years: Initially 1.5–2.5 mg/kg twice
daily, then adjusted according to response to
2.5–5 mg/kg twice daily (max. per dose 7.5 mg/kg twice
daily), dose also adjusted according to plasmaphenytoin concentration; maximum 300 mg per day
▶ Child 12–17 years: Initially 75–150 mg twice daily, then
adjusted according to response to 150–200 mg twice
daily (max. per dose 300 mg twice daily), dose also
adjusted according to plasma-phenytoin concentration
Tonic-clonic seizures | Focal seizures | Prevention and
treatment of seizures during or following neurosurgery
▶ Adult: Initially 3–4 mg/kg daily, alternatively
150–300 mg once daily, alternatively 150–300 mg daily
in 2 divided doses; usual maintenance 200–500 mg
daily, to be taken preferably with or after food, dose to
be increased gradually as necessary (with plasmaphenytoin concentration monitoring), exceptionally,
Prevention and treatment of seizures during or following
neurosurgery or severe head injury
▶ Child: Initially 2.5 mg/kg twice daily, then adjusted
according to response to 4–8 mg/kg daily, dose also
adjusted according to plasma-phenytoin
concentration; maximum 300 mg per day
Status epilepticus | Acute symptomatic seizures associated
with head trauma or neurosurgery
▶ INITIALLY BY SLOW INTRAVENOUS INJECTION, OR BY
▶ Child 1 month–11 years: Loading dose 20 mg/kg, then (by
slow intravenous injection or by intravenous infusion)
▶ Child 12–17 years: Loading dose 20 mg/kg, then (by
intravenous infusion or by slow intravenous injection)
▶ Adult: Loading dose 20 mg/kg (max. per dose 2 g), then
(by intravenous infusion or by slow intravenous
injection or by mouth) maintenance 100 mg every
6–8 hours adjusted according to plasma-concentration
DOSE EQUIVALENCE AND CONVERSION
▶ Preparations containing phenytoin sodium are not
bioequivalent to those containing phenytoin base
(such as Epanutin Infatabs ® and Epanutin ®
suspension); 100 mg of phenytoin sodium is
approximately equivalent in therapeutic effect to
92 mg phenytoin base. The dose is the same for all
phenytoin products when initiating therapy. However,
if switching between these products the difference in
phenytoin content may be clinically significant. Care is
needed when making changes between formulations
and plasma-phenytoin concentration monitoring is
▶ With oral use in children Licensed for use in children (age
range not specified by manufacturer).
▶ With intravenous use Phenytoin doses in BNF publications
may differ from those in product literature.
NHS IMPROVEMENT PATIENT SAFETY ALERT: RISK OF DEATH AND
SEVERE HARM FROM ERROR WITH INJECTABLE PHENYTOIN
Use of injectable phenytoin is error-prone throughout
the prescribing, preparation, administration and
monitoring processes; all relevant staff should be made
aware of appropriate guidance on the safe use of
injectable phenytoin to reduce the risk of error.
GENERAL CONTRA-INDICATIONS Acute porphyrias p. 1058
GENERAL CAUTIONS Enteral feeding (interrupt feeding for
2 hours before and after dose; more frequent monitoring
▶ With intravenous use Heart failure . hypotension . injection
solutions alkaline (irritant to tissues).respiratory
depression .resuscitation facilities must be available
CAUTIONS, FURTHER INFORMATION Consider vitamin D
supplementation in patients who are immobilised for long
periods or who have inadequate sun exposure or dietary
Intramuscular phenytoin should not be used (absorption
l INTERACTIONS → Appendix 1: antiepileptics
Agranulocytosis . bone disorders . bone fracture . bone
(maintain good oral hygiene). granulocytopenia . hair
nodosa . pseudolymphoma . sensory peripheral
polyneuropathy . severe cutaneous adverse reactions
(SCARs). skin reactions . systemic lupus erythematosus
(SLE) .taste altered .thrombocytopenia .tremor. vertigo . vomiting
▶ With oral use Electrolyte imbalance . pneumonitis . vitamin
▶ With parenteral use Arrhythmias . atrial conduction
depression (more common if injection too rapid). cardiac
arrest. extravasation necrosis . hypotension . injection site
necrosis . purple glove syndrome .respiratory arrest (more
injection too rapid). ventricular fibrillation (more common
SIDE-EFFECTS, FURTHER INFORMATION Rash Discontinue;
if mild re-introduce cautiously but discontinue
BNF 78 Epilepsy and other seizure disorders 323
Bradycardia and hypotension With intravenous use;
reduce rate of administration if bradycardia or
Overdose Symptoms of phenytoin toxicity include
nystagmus, diplopia, slurred speech, ataxia, confusion,
l ALLERGY AND CROSS-SENSITIVITY Cross-sensitivity
reported with carbamazepine. Antiepileptic
hypersensitivity syndrome associated with phenytoin. See
under Epilepsy p. 305 for more information.
l PREGNANCY See also Pregnancy in Epilepsy p. 305.
Monitoring Changes in plasma-protein binding make
interpretation of plasma-phenytoin concentrations
difficult—monitor unbound fraction.
Doses should be adjusted on the basis of plasma-drug
l BREAST FEEDING Small amounts present in milk, but not
l HEPATIC IMPAIRMENT Manufacturer advises caution
(increased risk of accumulation and toxicity due to
decreased protein binding in hepatic impairment,
hypoalbuminaemia, or hyperbilirubinaemia).
Dose adjustments ▶ With oral use Manufacturer advises
▶ With intravenous use Manufacturer advises consider
l PRE-TREATMENT SCREENING HLAB* 1502 allele in
individuals of Han Chinese or Thai origin—avoid unless
essential (increased risk of Stevens- Johnson syndrome).
▶ Blood counts Manufacturer recommends blood counts (but
evidence of practical value uncertain).
▶ In adults The usual total plasma-phenytoin concentration
for optimum response is 10–20 mg/litre (or
40–80 micromol/litre). In pregnancy, the elderly, and
certain disease states where protein binding may be
reduced, careful interpretation of total plasma-phenytoin
concentration is necessary; it may be more appropriate to
measure free plasma-phenytoin concentration.
▶ In children Therapeutic plasma-phenytoin concentrations
reduced in first 3 months of life because of reduced protein
binding. Trough plasma concentration for optimum
response: neonate–3 months, 6–15 mg/litre
(25–60 micromol/litre); child 3 months–18 years,
10–20 mg/litre (40–80 micromol/litre).
▶ With intravenous use Monitor ECG and blood pressure.
l DIRECTIONS FOR ADMINISTRATION Manufacturer advises
each injection or infusion should be preceded and followed
by an injection of Sodium Chloride 0.9% through the same
needle or catheter to avoid local venous irritation.
▶ With intravenous use in children g For intravenous
injection, give into a large vein at a rate not exceeding
1 mg/kg/minute (max. 50 mg/minute). k Manufacturer
advises for intravenous infusion, dilute to a concentration
not exceeding 10 mg/mL with Sodium Chloride 0.9% and
give into a large vein through an in-line filter
(0.22–0.50 micron).g Give at a rate not exceeding
1 mg/kg/minute (max. 50 mg/minute). k Complete
administration within 1 hour of preparation.
▶ With intravenous use in adults Manufacturer advises for
intravenous injection, give into a large vein at a rate not
exceeding 50 mg/minute; rate of 25 mg/minute or lower
may be more appropriate in some patients (including the
elderly and those with heart disease). Manufacturer
advises for intravenous infusion, dilute in 50–100 mL
Sodium Chloride 0.9% (final concentration not to exceed
10 mg/mL) and give into a large vein through an in-line
filter (0.22–0.50 micron) at a rate not exceeding
50 mg/minute; rate of 25 mg/minute or lower may be more
appropriate in some patients (including the elderly and
those with heart disease). Complete administration within
l PRESCRIBING AND DISPENSING INFORMATION
Switching between formulations Different formulations of oral
preparations may vary in bioavailability. Patients being
treated for epilepsy should be maintained on a specific
Blood or skin disorders Patients or their carers should be told
how to recognise signs of blood or skin disorders, and
advised to seek immediate medical attention if symptoms
such as fever, rash, mouth ulcers, bruising, or bleeding
develop. Leucopenia that is severe, progressive, or
associated with clinical symptoms requires withdrawal (if
necessary under cover of a suitable alternative).
Medicines for Children leaflet: Phenytoin for preventing seizures
www.medicinesforchildren.org.uk/phenytoin-preventingseizures
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug. Forms available
from special-order manufacturers include: oral suspension, oral
CAUTIONARY AND ADVISORY LABELS 8
Phenytoin sodium 100 mg Phenytoin sodium 100mg tablets |
28 tablet P £30.00 DT = £11.03
EXCIPIENTS: May contain Alcohol, propylene glycol
ELECTROLYTES: May contain Sodium
Phenytoin sodium 50 mg per 1 ml Phenytoin sodium 250mg/5ml
solution for injection ampoules | 5 ampoule P £24.40 (Hospital
Phenytoin sodium 50 mg per 1 ml Epanutin Ready-Mixed
Parenteral 250mg/5ml solution for injection ampoules |
10 ampoule P £48.79 (Hospital only)
CAUTIONARY AND ADVISORY LABELS 8
Phenytoin 6 mg per 1 ml Epanutin 30mg/5ml oral suspension | 500 ml P £4.27 DT = £4.27
CAUTIONARY AND ADVISORY LABELS 8, 24
Phenytoin 50 mg Epanutin Infatabs 50mg chewable tablets | 200 tablet P £13.18 DT = £13.18
CAUTIONARY AND ADVISORY LABELS 8
Phenytoin sodium 25 mg Phenytoin sodium 25mg capsules | 28 capsule P £7.24 DT = £7.24
Phenytoin sodium 50 mg Phenytoin sodium 50mg capsules | 28 capsule P £7.07 DT = £7.07
Phenytoin sodium 100 mg Phenytoin sodium 100mg capsules |
84 capsule P £67.50 DT = £8.36
Phenytoin sodium 300 mg Phenytoin sodium 300mg capsules | 28 capsule P £9.11 DT = £9.11
Peripheral and central neuropathic pain
▶ Adult: Initially 150 mg daily in 2–3 divided doses, then
increased if necessary to 300 mg daily in 2–3 divided
doses, dose to be increased after 3–7 days, then
increased if necessary up to 600 mg daily in 2–3 divided
doses, dose to be increased after 7 days
324 Epilepsy and other seizure disorders BNF 78
Adjunctive therapy for focal seizures with or without
▶ Adult: Initially 25 mg twice daily, then increased in
steps of 50 mg daily, dose to be increased at 7 day
intervals, increased to 300 mg daily in 2–3 divided
doses for 7 days, then increased if necessary up to
600 mg daily in 2–3 divided doses
▶ Adult: Initially 150 mg daily in 2–3 divided doses, then
increased in steps of 150 mg daily if required, dose to
be increased at 7 day intervals, increased if necessary
up to 600 mg daily in 2–3 divided doses
l UNLICENSED USE Pregabalin doses in BNF may differ from
MHRA/CHM ADVICE: PREGABALIN (LYRICA ®) AND RISK OF ABUSE
AND DEPENDENCE: NEW SCHEDULING REQUIREMENTS FROM 1
Following concerns about abuse, pregabalin has been
reclassified as a Class C controlled substance and is now
a Schedule 3 drug, but is exempt from safe custody
requirements. Healthcare professionals should evaluate
patients carefully for a history of drug abuse before
prescribing pregabalin, and observe patients for signs of
abuse and dependence. Patients should be informed of
the potentially fatal risks of interactions between
pregabalin and alcohol, and with other medicines that
cause CNS depression, particularly opioids.
l CAUTIONS Conditions that may precipitate
encephalopathy . history of substance abuse . severe
l INTERACTIONS → Appendix 1: antiepileptics
▶ Common or very common Abdominal distension . appetite
abnormal . asthenia . cervical spasm . concentration
disorders . speech impairment. vertigo . vision disorders . vomiting . weight changes
▶ Frequency not known Drug use disorders
l PREGNANCY Manufacturer advises avoid unless potential
benefit outweighs risk — toxicity in animal studies. See
also Pregnancy in Epilepsy p. 305.
l BREAST FEEDING See Breast-feeding in Epilepsy p. 305.
Dose adjustments Initially 75 mg daily and maximum
300 mg daily if eGFR 30–60 mL/minute/1.73 m2
Initially 25–50 mg daily and maximum 150 mg daily in
1–2 divided doses if eGFR 15–30 mL/minute/1.73 m2
Initially 25 mg once daily and maximum 75 mg once
daily if eGFR less than 15 mL/minute/1.73 m2
l MONITORING REQUIREMENTS Monitor for signs of
l TREATMENT CESSATION Avoid abrupt withdrawal (taper
l PRESCRIBING AND DISPENSING INFORMATION Flavours of
oral liquid formulations may include strawberry.
Patient leaflet NHS England has produced a patient leaflet
with information on the reclassification of pregabalin.
l NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) decisions
The Scottish Medicines Consortium has advised (July 2007)
that pregabalin (Lyrica ®) is not recommended for the
treatment of central neuropathic pain.
The Scottish Medicines Consortium has advised (April
2009) that pregabalin (Lyrica ®) is accepted for restricted
use within NHS Scotland for the treatment of peripheral
neuropathic pain in adults who have not achieved
adequate pain relief with, or have not tolerated, first- or
second-line treatments; discontinue treatment if sufficient
benefit is not achieved within 8 weeks of reaching the
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug. Forms available
from special-order manufacturers include: oral suspension, oral
CAUTIONARY AND ADVISORY LABELS 3, 8
▶ Pregabalin (Non-proprietary)
Pregabalin 20 mg per 1 ml Pregabalin 20mg/ml oral solution sugar
free sugar-free | 473 ml P £99.48 DT = £99.48c | 500 ml
P £75.00–£105.16c ▶ Lyrica (Pfizer Ltd)
Pregabalin 20 mg per 1 ml Lyrica 20mg/ml oral solution sugar-free
| 473 ml P £99.48 DT = £99.48c
CAUTIONARY AND ADVISORY LABELS 3, 8
▶ Pregabalin (Non-proprietary)
Pregabalin 50 mg Pregabalin 50mg capsules | 56 capsule P £8.96c | 84 capsule P £96.60 DT = £3.40c
Pregabalin 75 mg Pregabalin 75mg capsules | 14 capsule P £3.21c | 56 capsule P £64.40 DT = £2.83c
Pregabalin 100 mg Pregabalin 100mg capsules | 84 capsule P £96.60 DT = £4.27c
Pregabalin 150 mg Pregabalin 150mg capsules | 56 capsule P £64.40 DT = £3.67c
Pregabalin 200 mg Pregabalin 200mg capsules | 84 capsule P £96.60 DT = £5.21c
Pregabalin 225 mg Pregabalin 225mg capsules | 56 capsule P £64.40 DT = £3.99c
Pregabalin 25 mg Alzain 25mg capsules | 56 capsule P £4.99 DT
Pregabalin 50 mg Alzain 50mg capsules | 56 capsule P £5.99c | 84 capsule P £6.99 DT = £3.40c
Pregabalin 75 mg Alzain 75mg capsules | 56 capsule P £5.99 DT
Pregabalin 100 mg Alzain 100mg capsules | 84 capsule P £6.99
Pregabalin 150 mg Alzain 150mg capsules | 56 capsule P £6.99
Pregabalin 200 mg Alzain 200mg capsules | 84 capsule P £8.99
BNF 78 Epilepsy and other seizure disorders 325
Pregabalin 225 mg Alzain 225mg capsules | 56 capsule P £7.99
Pregabalin 300 mg Alzain 300mg capsules | 56 capsule P £8.99
DT = £4.92c ▶ Axalid (Kent Pharmaceuticals Ltd)
Pregabalin 25 mg Axalid 25mg capsules | 56 capsule P £19.95
Pregabalin 50 mg Axalid 50mg capsules | 56 capsule P £19.95c
Pregabalin 75 mg Axalid 75mg capsules | 56 capsule P £19.95
Pregabalin 100 mg Axalid 100mg capsules | 56 capsule P £19.95c
Pregabalin 150 mg Axalid 150mg capsules | 56 capsule P £19.95 DT = £3.67c
Pregabalin 200 mg Axalid 200mg capsules | 56 capsule P £19.95c
Pregabalin 225 mg Axalid 225mg capsules | 56 capsule P £19.95 DT = £3.99c
Pregabalin 300 mg Axalid 300mg capsules | 56 capsule P £19.95 DT = £4.92c ▶ Lecaent (Actavis UK Ltd)
Pregabalin 25 mg Lecaent 25mg capsules | 56 capsule P £64.39
DT = £2.98c | 84 capsule P £96.59c
Pregabalin 50 mg Lecaent 50mg capsules | 84 capsule P £96.59 DT = £3.40c
Pregabalin 75 mg Lecaent 75mg capsules | 56 capsule P £64.39
Pregabalin 100 mg Lecaent 100mg capsules | 84 capsule P £96.59 DT = £4.27c
Pregabalin 150 mg Lecaent 150mg capsules | 56 capsule P £64.39 DT = £3.67c
Pregabalin 200 mg Lecaent 200mg capsules | 84 capsule P £96.59 DT = £5.21c
Pregabalin 225 mg Lecaent 225mg capsules | 56 capsule P £64.39 DT = £3.99c
Pregabalin 300 mg Lecaent 300mg capsules | 56 capsule P £64.39 DT = £4.92c ▶ Lyrica (Pfizer Ltd)
Pregabalin 25 mg Lyrica 25mg capsules | 56 capsule P £64.40
DT = £2.98c | 84 capsule P £96.60c
Pregabalin 50 mg Lyrica 50mg capsules | 84 capsule P £96.60
Pregabalin 75 mg Lyrica 75mg capsules | 56 capsule P £64.40
Pregabalin 100 mg Lyrica 100mg capsules | 84 capsule P £96.60 DT = £4.27c
Pregabalin 150 mg Lyrica 150mg capsules | 56 capsule P £64.40 DT = £3.67c
Pregabalin 200 mg Lyrica 200mg capsules | 84 capsule P £96.60 DT = £5.21c
Pregabalin 225 mg Lyrica 225mg capsules | 56 capsule P £64.40 DT = £3.99c
Pregabalin 300 mg Lyrica 300mg capsules | 56 capsule P £64.40 DT = £4.92c
Adjunctive treatment of seizures in Lennox-Gastaut
syndrome without valproate (initiated by a specialist)
▶ Child 1–3 years: Initially 5 mg/kg twice daily, then
increased in steps of up to 5 mg/kg twice daily (max.
per dose 22.5 mg/kg twice daily), adjusted according to
response, dose to be increased at intervals of not less
than 3 days to the target dose (maximum dose), each
dose should be given to the nearest 0.5 mL
▶ Child 4–17 years (body-weight up to 30 kg): Initially
100 mg twice daily, then increased in steps of 100 mg
twice daily (max. per dose 500 mg twice daily), adjusted
according to response, dose to be increased at intervals
▶ Child 4–17 years (body-weight 30–50 kg): Initially 200 mg
twice daily, then increased in steps of 200 mg twice
daily (max. per dose 900 mg twice daily), adjusted
according to response, dose to be increased at intervals
▶ Child 4–17 years (body-weight 50.1–70 kg): Initially 200 mg
Comments
Post a Comment
اكتب تعليق حول الموضوع